<DOC>
	<DOCNO>NCT00850122</DOCNO>
	<brief_summary>This phase I open label multi-dose study investigative pharmacokinetics safety cefazolin infant &lt; 121 day age &lt; 28 week gestation suspect sepsis . There two cohort 6 infant : 1 ) &gt; 48 hour age ≤28 day 2 ) &gt; 28 day age &lt; 121 day age . The study require administration study drug 2 day follow 1 week safety monitoring . Six 200 µL pK sample obtain 2 day drug administration . The risk reasonable vs. benefit minimize appropriately . There may benefit subject ( administration empirical antimicrobial therapy ) , information study may benefit large number infant drug currently administer despite lack PK data population .</brief_summary>
	<brief_title>An Open Label Study Describe Pharmacokinetics Cefazolin Preterm Neonates</brief_title>
	<detailed_description />
	<mesh_term>Cefazolin</mesh_term>
	<criteria>&lt; 28 week gestation birth &gt; 48 hour &lt; 121 day age time study drug administration One following : Suspected systemic infection Receiving cefazolin prophylaxis Receiving cefazolin treatment systemic infection History anaphylaxis attribute βlactam Exposure cefazolin month prior study Serum creatinine &gt; 1.7 mg/dL</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>120 Days</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>